AU2005309807B2 - 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses - Google Patents

2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses Download PDF

Info

Publication number
AU2005309807B2
AU2005309807B2 AU2005309807A AU2005309807A AU2005309807B2 AU 2005309807 B2 AU2005309807 B2 AU 2005309807B2 AU 2005309807 A AU2005309807 A AU 2005309807A AU 2005309807 A AU2005309807 A AU 2005309807A AU 2005309807 B2 AU2005309807 B2 AU 2005309807B2
Authority
AU
Australia
Prior art keywords
compound
hydroxy
formula
hydrogen
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005309807A
Other languages
English (en)
Other versions
AU2005309807A1 (en
Inventor
Margaret Clagett-Dame
Hector F. Deluca
Sumithra Gowlugari
Lori A. Plum
Rafal R. Sicinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2005309807A1 publication Critical patent/AU2005309807A1/en
Application granted granted Critical
Publication of AU2005309807B2 publication Critical patent/AU2005309807B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2005309807A 2004-11-22 2005-11-18 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses Ceased AU2005309807B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63018104P 2004-11-22 2004-11-22
US60/630,181 2004-11-22
PCT/US2005/041821 WO2006057902A2 (en) 2004-11-22 2005-11-18 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses

Publications (2)

Publication Number Publication Date
AU2005309807A1 AU2005309807A1 (en) 2006-06-01
AU2005309807B2 true AU2005309807B2 (en) 2011-09-29

Family

ID=36216925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005309807A Ceased AU2005309807B2 (en) 2004-11-22 2005-11-18 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses

Country Status (8)

Country Link
US (1) US8399438B2 (enExample)
EP (1) EP1838667A2 (enExample)
JP (1) JP2008520706A (enExample)
AU (1) AU2005309807B2 (enExample)
CA (1) CA2588412A1 (enExample)
MX (1) MX2007006545A (enExample)
NZ (1) NZ555279A (enExample)
WO (1) WO2006057902A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555283A (en) * 2004-11-22 2010-12-24 Wisconsin Alumni Res Found 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
WO1999003829A1 (en) * 1997-07-21 1999-01-28 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin d compounds
US6579861B2 (en) * 2000-09-08 2003-06-17 Wisconsin Alumni Research Foundation 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
DE69606680T2 (de) * 1995-10-30 2000-08-17 F. Hoffmann-La Roche Ag, Basel 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
ES2309069T3 (es) * 2000-05-31 2008-12-16 Wisconsin Alumni Research Foundation Compuestos de 2-etil y 2-etiliden-19-nor-vitamina d.
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
ATE508750T1 (de) * 2005-12-12 2011-05-15 Women And Infants Hospital Of Rhode Island Derivate von vitamin d und ihre verwendung in der therapie

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
WO1999003829A1 (en) * 1997-07-21 1999-01-28 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin d compounds
US6281249B1 (en) * 1997-07-21 2001-08-28 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
US6579861B2 (en) * 2000-09-08 2003-06-17 Wisconsin Alumni Research Foundation 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI M. et al. Chemistry & Biology, vol. 10, 2003, pp. 261-270. *
DELUCA H F., J. Steroid Biochemistry & Molecular Biology, 2004, vol. 89/90 (1-5), pp. 67-73. *

Also Published As

Publication number Publication date
WO2006057902A2 (en) 2006-06-01
NZ555279A (en) 2010-12-24
WO2006057902A3 (en) 2006-07-13
CA2588412A1 (en) 2006-06-01
JP2008520706A (ja) 2008-06-19
AU2005309807A1 (en) 2006-06-01
US20060148759A1 (en) 2006-07-06
MX2007006545A (es) 2007-09-21
EP1838667A2 (en) 2007-10-03
US8399438B2 (en) 2013-03-19

Similar Documents

Publication Publication Date Title
US8093232B2 (en) 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses
US8614202B2 (en) 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses
US20070249567A1 (en) 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses
US7718637B2 (en) (20S)-23,23-difluoro-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs
US20060111321A1 (en) 2-Methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses
EP2069296B1 (en) 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs
US7893043B2 (en) 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
EP1817278B1 (en) 2-methylene-18,19-dinor-1alfa-hydroxy-homopregnacalciferol and its uses
US8399438B2 (en) 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses
US8222236B2 (en) 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
US7888339B2 (en) 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US7947666B2 (en) 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs
US8193169B2 (en) (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTOR GOWLUGARI, SUMITHRA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired